Human medicines European public assessment report (EPAR): Trodelvy, sacituzumab govitecan, Date of authorisation: 22/11/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Trodelvy, sacituzumab govitecan, Date of authorisation: 22/11/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Exjade, deferasirox, Date of authorisation: 28/08/2006, Revision: 55, Status: Authorised

Human medicines European public assessment report (EPAR): Exjade, deferasirox, Date of authorisation: 28/08/2006, Revision: 55, Status: Authorised

Human medicines European public assessment report (EPAR): Dasatinib Accord Healthcare, dasatinib, Date of authorisation: 26/07/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Dasatinib Accord Healthcare, dasatinib, Date of authorisation: 26/07/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Fampyra, fampridine, Date of authorisation: 20/07/2011, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Fampyra, fampridine, Date of authorisation: 20/07/2011, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Spevigo, spesolimab, Date of authorisation: 09/12/2022, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Spevigo, spesolimab, Date of authorisation: 09/12/2022, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 25, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.